



PRODUCT
BROCHURE

2% chlorhexidine digluconate in
70% isopropyl alcohol impregnated pad

SIMPLE SKIN DISINFECTION

A sterile pad licensed for skin disinfection
before invasive procedures.

from the makers of **clinell**

STERILE

Choosing cost or compliance?

Skin antisepsis is a critical part of the process to prevent infections during breaches of the skin barrier. Contamination from inadequate skin antisepsis may adversely impact patient safety and care.

NICE¹, epic3² and other guidelines aim to make skin disinfection safer. epic3 recommend using 2% chlorhexidine in 70% alcohol as a gold standard before invasive vascular access procedures.

HEXI PREP as a sterile licensed pharmaceutical product is compliant in providing therapeutic indications for skin antisepsis. HEXI PREP now offers the clinical community an alternative choice of licensed product to use for skin disinfection prior to invasive procedures.

What is HEXI PREP?

HEXI PREP is a sterile impregnated pad containing 2% chlorhexidine digluconate in 70% isopropyl alcohol. It's a licensed pharmaceutical, indicated for skin disinfection before invasive vascular access procedures.



Simple

HEXI PREP's 'apply & dry' application method makes skin disinfection straightforward for the user.

Licensed

Our 1.5ml and 3.0ml sachets are licensed for a wide range of vascular access procedures, streamlining your skin disinfection solutions³.

ANTT[®] approved

Evaluated by ANTT^{®4} to make sure HEXI PREP supports good aseptic practice.

Advantages of HEXI PREP

COST-EFFECTIVE CARE

HEXI PREP's glass-free compact presentation focuses on reduced plastic, packaging, and volume of waste thus assisting in reducing the Trust's waste management burden. HEXI PREP's size supports access at point of care and compliance.



STAY COMPLIANT

HEXI PREP is a clinically proven licensed pharmaceutical. It facilitates compliance with epic3 guidelines and maintains effective aseptic practice during application². IVAD15 recommends using 2% chlorhexidine digluconate in 70% isopropyl alcohol to disinfect areas of a patient's skin before inserting a peripheral vascular access device².



STRAIGHT FORWARD SKIN DISINFECTION

HEXI PREP's 'apply & dry', skin disinfection pad can be used readily and intuitively with standard ANTT approach³. HEXI PREP's fast dry time and long-lasting residual protection⁵ make it suitable for many different types of vascular access procedures.



Licensed indications

Sachet volume/ Impregnated pad size/ Product code	Maximum coverage area	For procedures such as:	
HEXI PREP 1.5mL (10cm x 10cm) CHEX15	10cm x 13cm	<ul style="list-style-type: none"> - blood culture collection - peripheral cannulation - peripheral arterial line cannulation 	<ul style="list-style-type: none"> - simple biopsy - routine venepuncture - dialysis/fistula/graft site cleansing
HEXI PREP 3.0mL (20cm x 10cm) CHEX30	15cm x 15cm	<ul style="list-style-type: none"> - blood culture collection - peripheral cannulation - peripheral arterial line cannulation - midline and central venous catheter (CVC) insertion and maintenance - simple biopsy 	<ul style="list-style-type: none"> - routine venepuncture - dialysis/fistula/graft site cleansing, peritoneal dialysis site cleansing - implantable device placement

Book a trial or consultation

For more information, product demonstrations or advice about how you could adopt HEXI PREP into your organisation, please contact your local GAMA Healthcare Area Manager, or visit

www.gamahealthcare.com/HEXI-PREP



Scan here

To book your product demonstration today

Order information

PRODUCT CODE	NHSSC CODE	UNIT OF ISSUE	PAD SIZE
CHEX15	DMK004	Box of 100 sachets (each containing 1.5 ml pre-impregnated pads)	100 x 100 mm
CHEX30	DMK003	Box of 50 sachets (each containing 3.0 ml pre-impregnated pads)	200 x 100 mm

Prescribing information: HEXI PREP 2% w/v / 70% v/v for cutaneous use. Refer to Summary of Product Characteristics before prescribing. **Presentation:** Each impregnated pad contains 1.5 ml or 3.0 ml of 20 mg chlorhexidine digluconate and 0.7 ml of isopropyl alcohol. **Indication:** Disinfection of the skin prior to invasive medical procedures that do not require a clean air environment. **Dosage & administration:** There are two pad sizes available. HEXI PREP may be used on all age groups and patient populations. Use with care in newborn babies, especially those born prematurely. The choice of pad size will depend on the size of the area to be disinfected, the invasive procedure and the clinician's preference. For both non-sterile and sterile procedures, the user should wear gloves during application. Keep the pad folded and press firmly against the skin on the intended area and wipe back and forth for a total of 30 seconds. Allow to air dry completely. It is recommended that HEXI PREP solution remains on the skin post-procedure to provide continued antimicrobial activity. If removal is necessary, remove with soap and water or alcohol. **Contraindications:** The medicinal product is contraindicated where patients have shown previous hypersensitivity to chlorhexidine or isopropyl alcohol. **Warnings & precautions:** The solution is flammable. Do not use with electrocautery procedures or other ignition sources until dry. Remove any soaked materials, drapes or gowns before proceeding with the intervention. Do not allow the solution to pool in skin folds or under the patient or drip onto sheets or other material in direct contact with the patient. Where occlusive dressings are to be applied to areas previously exposed to HEXI PREP, care must be taken to ensure no excess product is present prior to application of the dressing. For external use only on intact skin. Do not use on open skin wounds. Avoid prolonged contact with the skin. Do not use on broken or damaged skin. Avoid contact with neural tissue, the middle ear, the eyes and mucous membranes. Chlorhexidine-containing products are known causes of anaphylactic reactions during anaesthesia. The symptoms of anaphylactic reactions might be masked in an anaesthetised patient. If symptoms of an anaphylactic reaction are detected during anaesthesia, chlorhexidine-related allergic reactions should be considered. When chlorhexidine-related reaction during anaesthesia is suspected, other products containing chlorhexidine used during anaesthesia (e.g. IV lines) should be removed. Special precaution should be taken to avoid patient exposure to any other product containing chlorhexidine during the course of the treatment. The use of chlorhexidine solutions, both alcohol based and aqueous, for skin antisepsis prior to invasive medical procedures has been associated with chemical burns in neonates. Based on available case reports and the published literature, this risk appears to be higher in preterm infants, especially those born before 32 weeks of gestation and within the first 2 weeks of life. **Pregnancy & lactation:** There are no studies with this product in pregnant or lactating women. No effects during pregnancy are anticipated since systemic exposure to chlorhexidine digluconate is negligible. HEXI PREP can be used during pregnancy. No effects on the breastfed newborn infant are anticipated since the systemic exposure of breast-feeding women to chlorhexidine digluconate is negligible. HEXI PREP can be used during lactation. **Undesirable effects:** Skin disorders: very rare allergic or irritation skin reactions have been reported with chlorhexidine and isopropylalcohol: erythema, rash (e.g. erythematous, papular, or maculopapular), pruritus and blisters or application site vesicles. Other local symptoms have included skin burning sensation, pain and inflammation. Frequency not known: dermatitis, eczema, urticaria, chemical burns in neonates. Immune disorders: Frequency unknown: Hypersensitivity including anaphylactic shock. Cases of anaphylactic reactions have been reported during anaesthesia. Common reported reactions: associated with site reactions often within the area of application and very rarely spread. This product may cause a severe allergic reaction. Symptoms may include wheezing / difficulty breathing, shock, facial swelling, hives or rash. Use of HEXI PREP is contraindicated where patients have shown previous hypersensitivity to chlorhexidine or isopropyl alcohol. If hypersensitivity or an allergic reaction occurs, stop use and seek medical help right away. **Reporting adverse events:** Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GAMA Healthcare Ltd. **Per pad costs** (NHS Supply Chain; ex VAT): HEXI PREP(CHEX15) 1.5 ml UK £0.28, HEXI PREP (CHEX30) 3.0 ml UK £0.66. **Legal category:** UK GSL. **Marketing Authorisation Numbers:** HEXI PREP (PL 40867/0002). **Marketing Authorisation Holder:** GAMA Healthcare Ltd., Maylands Building, Maylands Avenue, Hemel Hempstead Industrial Estate, Hemel Hempstead, Hertfordshire, HP2 7TG. **Date of issue:** May 2023.

References

1. *Healthcare-associated infections: prevention and control in primary and community care.* London: National Institute for Health and Care Excellence (NICE); February 2017.
2. Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. *J Hosp Infect.* 2014;1(86):S1-70.
3. MHRA Grant of Marketing Authorisation 23/12/2020.
4. ASAP Product evaluation programme (PEP). The Association of Safe Aseptic Practice. 5th of March 2021. Confidential report. (Data on file).
5. HEXI PREP Skin disinfection, summary of product characteristics, 2021.

About GAMA Healthcare

HEXI PREP is designed and developed by GAMA Healthcare, a multinational infection prevention healthcare company; with over 17 years of infection prevention experience and creators of trusted brands such as Clinell.

For more information on us, visit

www.gamahealthcare.com

JBN220678 Revised Date: 19-Jun-2023

Use product safely. Always read the prescribing information before use.

GAMA Healthcare Ltd.,
The Maylands Building, Maylands Avenue, Hemel Hempstead, Hertfordshire, HP2 7TG, UK.
T: +44 (0)20 7993 0030 E: info@gamahealthcare.com

gama
healthcare